Formulation And Evaluation Of Buccal Film Of Vortioxetine Hydrobromide

Vortioxetine hydrobromide is an atypical antidepressant used in the treatment of major depressive disorder (MDD).However, its oral bioavailability is limited due to poor solubility and first-pass metabolism.To address these challenges, a buccal film formulation of vortioxetine hydrobromide was developed.Buccal films offer a convenient, patient-friendly alternative to oral tablets, providing improved bioavailability due to direct absorption through the buccal mucosa.The formulation was designed to enhance drug release, optimize the physicochemical properties, and ensure stability.This research focuses on the formulation, evaluation, and potential therapeutic benefits of buccal films for vortioxetine hydrobromide.